Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M

doi:10.1002/hep.21505

Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

ORCIDs linked to this article

Show all (6)

Hepatology (Baltimore, Md.), 01 Jan 2007, 45(1):258-259
https://doi.org/10.1002/hep.21505 PMID: 17187414

This is a comment on "Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy." Hepatology. 2006 May;43(5):954-60.

Abstract

No abstract provided.

Full text links

Read article at publisher's site: https://doi.org/10.1002/hep.21505

References

Articles referenced by this article (3)

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B
Hepatology, (5):954-960 2006
MED: 16628671
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU; DITTO-HCV Study Group
J Hepatol, (2):250-257 2005
MED: 16082736
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J
J Hepatol, (1):97-103 2005
MED: 16290907

Citations & impact

Impact metrics

Citations

Jump to Citations

Citations of article over time

Article citations

Performance of two Real-Time RT-PCR assays for quantitation of hepatitis C virus RNA: evaluation on HCV genotypes 1-4.
Elkady A, Tanaka Y, Kurbanov F, Sugauchi F, Sugiyama M, Khan A, Ali EM, Mouhamed L, Abou el-fetouh S, AbdEl-Hameed AR, Mizokami M
J Med Virol, 82(11):1878-1888, 01 Nov 2010
Cited by: 17 articles | PMID: 20872714
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.
El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H
Hepatology, 48(1):38-47, 01 Jul 2008
Cited by: 101 articles | PMID: 18537193
Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.
Nakamura M, Saito H, Ikeda M, Tada S, Kumagai N, Kato N, Shimotohno K, Hibi T
J Med Virol, 80(4):632-639, 01 Apr 2008
Cited by: 8 articles | PMID: 18297719
Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay.
Pittaluga F, Allice T, Abate ML, Ciancio A, Cerutti F, Varetto S, Colucci G, Smedile A, Ghisetti V, Ghisetti V
J Med Virol, 80(2):254-260, 01 Feb 2008
Cited by: 23 articles | PMID: 18098148

Search life-sciences literature (45,103,589 articles, preprints and more)

Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

ORCIDs linked to this article

Abstract

Full text links

References

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

Citations & impact

Impact metrics

Citations of article over time

Article citations

Performance of two Real-Time RT-PCR assays for quantitation of hepatitis C virus RNA: evaluation on HCV genotypes 1-4.

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.

Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.

Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay.

Similar Articles

Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

Peginterferon and ribavirin for chronic hepatitis C.

Partnerships & funding

Similar Articles

Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
Hepatology, 48(3):1019-20; author reply 1020-1, 01 Sep 2008

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
J Hepatol, 46(3):403-410, 07 Nov 2006

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
AIDS, 22(1):15-21, 01 Jan 2008

Peginterferon and ribavirin for chronic hepatitis C.
N Engl J Med, 355(23):2444-2451, 01 Dec 2006

Search life-sciences literature (45,103,589 articles, preprints and more)

Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

Author information

ORCIDs linked to this article

Abstract

Full text links

References

Citations & impact

Impact metrics

Citations of article over time

Article citations

Similar Articles

Partnerships & funding